Rothkopf M, Lenk S, Kalweit H
Z Gesamte Inn Med. 1978 Oct 1;33(19):696-701.
The present therapy of the urogenital tuberculosis is based on the effective medicaments (rifampizin, isonicotinic acid hydrazid, streptomycin, and ethambutol). It rests on an optimum dosage in connection with a best suited combination, taking into consideration the relations of sensitiveness and side effects as well as consequent long-term treatment. It is referred to the possibility of additional administrations of corticosteroid preparations and it is taken notice to the necessity also to treat unspecific mixed infections. Under the modern chemotherapy with bactericidal effect a stable negativation practically always develops within 3 months. Actual recidivations were not seen during the last 12 years. Apart from a compilation of the indications to nephrectomy references to possibilities of plastic surgical corrections of the urinary system are given. Two tables give information about the patients who were operatively treated during the last 15 years. A close collaboration of the various therapeutic institutions with a consulting urologist -- particularly in problematic and advanced cases of the disease -- nearly always saves the patient with urogenital tuberculosis from invalidism.
目前泌尿生殖系统结核的治疗基于有效的药物(利福平、异烟肼、链霉素和乙胺丁醇)。它取决于最佳剂量与最适宜组合的结合,同时考虑敏感性和副作用的关系以及随之而来的长期治疗。它涉及到额外使用皮质类固醇制剂的可能性,并且注意到治疗非特异性混合感染的必要性。在具有杀菌作用的现代化疗下,实际上在3个月内几乎总能实现稳定的转阴。在过去12年中未见到实际的复发情况。除了汇编肾切除术的适应证外,还提及了泌尿系统整形手术矫正的可能性。两张表格提供了过去15年接受手术治疗患者的信息。各个治疗机构与咨询泌尿科医生密切合作——特别是在该疾病的疑难和晚期病例中——几乎总能使泌尿生殖系统结核患者免于残疾。